Recent News

• 03.12.2026 - HeartBeam Reports Fourth Quarter and Full Year 2025 Results
• 03.10.2026 - HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home
• 03.09.2026 - HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch
• 03.05.2026 - HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study
• 03.04.2026 - HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time
• 03.04.2026 - HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market
• 01.22.2026 - HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer
• 01.05.2026 - HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
• 12.10.2025 - HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
• 11.26.2025 - HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

Recent Filings

• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.09.2026 - S-3 Registration statement under Securities Act of 1933
• 12.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities